InMed Pharmaceuticals Inc.

INM Healthcare Drug Manufacturers Specialty & Generic

In the quarter to June 2026, revenue fell 26.2%, EPS fell 1,621.7%, free cash flow fell 40.4% and total debt fell 92.7%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

1.32 0.01 −0.75%
Market cap
$7.3M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
5/9
Altman Z
−10.27
Beneish M
−2.54
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

4 3 — —
ROE
(82.17%) (97.20%) (122.32%) (179.09%)
ROA
(68.92%) (77.83%) (92.43%) (139.63%)
ROIC
(156.22%) (138.03%) (244.94%) 0.00%
Return on Tangible Assets
(81.09%) (94.94%) (159.97%) (1,378.37%)
Average Days of Receivables
20.69 11.58 — —
Free Cash Flow per Share
(1.99) (1.96) (1.92) (2.08)
Free Cash Flow
(7.88) (7.75) (7.79) (8.64)
Other line items

Show all line items

Columns are period end dates